Luis-Esteban Tamariz-Amador

11PUBLICATIONS
150CO-AUTHORS
Medical mycologyInnate immunityMedical bacteriologyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 23, 2026
Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response.

|Jan 29, 2026
Immune biomarkers of increased infection risk in multiple myeloma.

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos

|Dec 17, 2025
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.

Tomas Jelinek, David Zihala, Aintzane Zabaleta

|Nov 14, 2025
Emerging Risk of Campylobacter spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies.

Idoia Bilbao, María Ansón, Sara Villar

|Nov 16, 2024
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.

Aintzane Zabaleta, Noemi Puig, Maria-Teresa Cedena

|Sep 23, 2024
A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies.

Aintzane Zabaleta, Laura Blanco, Peter S Kim

Pageof 2

Frequent Collaborators

8 joint publications

Jesus San-Miguel

8 joint publications

Bruno Paiva

7 joint publications

Paula Rodriguez-Otero

5 joint publications

Felipe Prosper